"L’Institut du Cancer de Montpellier (ICM) est le centre de référence en Occitanie-Est, reconnu au niveau national pour son expertise et son innovation dans la prise en charge et le traitement des patients atteints de cancers : cancer du sein, cancers digestifs (colon, rectum, pancréas…), cancers gynécologiques (col de l’utérus, ovaires…), cancer de la prostate, cancer du poumon, sarcomes, cancer ORL... La prise en charge et l’accompagnement des patients atteints de cancer à Montpellier et dans toute la région est assurée par des équipes médicales pluridisciplinaires spécialisées. Il regroupe des unités de soins, de prévention, de recherche clinique, translationnelle et fondamentale en cancérologie. L’ICM fait partie du réseau UNICANCER."

During the past decade, Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle conducted 283 clinical trials. In the 10-year time frame, 283 clinical trials started and 28 clinical trials were completed, i.e. on average, 9.9% percent of trials that started reached the finish line to date. In the past 5 years, 128 clinical trials started and 22 clinical trials were completed. i.e. 17.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle" #1 sponsor was "Institut du Cancer de Montpellier - Val d'Aurelle" with 99 trials, followed by "UNICANCER" with 74 trials sponsored, "Hoffmann-La Roche" with 24 trials sponsored, "Institut Claudius Regaud" with 20 trials sponsored and "ARCAGY/ GINECO GROUP" with 20 trials sponsored. Other sponsors include 211 different institutions and companies that sponsored additional 90 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle" #1 collaborator was "AstraZeneca" with 20 trials as a collaborator, "National Cancer Institute, France" with 14 trials as a collaborator, "Merck Sharp & Dohme LLC" with 9 trials as a collaborator, "ARCAGY/ GINECO GROUP" with 8 trials as a collaborator and "Hoffmann-La Roche" with 8 trials as a collaborator. Other collaborators include 312 different institutions and companies that were collaborators in the rest 212 trials.

According to Clinical.Site data, the most researched conditions in "Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle" are "Breast Cancer" (70 trials), "Colorectal Cancer" (23 trials), "Prostate Cancer" (23 trials), "Ovarian Cancer" (19 trials) and "Cancer" (16 trials). Many other conditions were trialed in "Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle" in a lesser frequency.

Most popular intervention types in "Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle" are "Drug" (284 trials), "Other" (78 trials), "Procedure" (73 trials), "Radiation" (64 trials) and "Biological" (43 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (27 trials), "fluorouracil" (25 trials), "radiation therapy" (22 trials), "Paclitaxel" (21 trials) and "Bevacizumab" (18 trials). Other intervention names were less common.

The vast majority of trials in "Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle" are 297 trials for "All" genders, 121 trials for "Female" genders and 32 trials for "Male" genders.

Currently, there are NaN active trials in "Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle". 2 are not yet recruiting, 119 are recruiting, 82 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 192 completed trials in Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, 5 suspended trials, and 28 terminated clinical trials to date.

Out of the total trials that were conducted in Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle, 43 "Phase 1" clinical trials were conducted, 152 "Phase 2" clinical trials and 134 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 101 trials that are defined as “Not Applicable".